Efficacy of Xueshuantong combined with edaravone dexborneol in treating patients with acute large-artery atherosclerotic cerebral infarction
LI Xin
LI Dongxu
LIN Huaiyin
ZHANG Weiwen
Abstract：Objective To investigate the efficacy of Xueshuantong combined with edaravone dexborneol in the treat-ment of acute large-artery atherosclerotic cerebral infarction(ALACI).Methods A total of 138 patients with ALACI admitted to the Second People's Hospital of Hengshui from January 2023 to February 2025 were enrolled in this prospective randomized controlled trial.They were randomly assigned to the observation group(Xueshuantong combined with edaravone dexborneol,69 cases)and the control group(edaravone dexborneol alone,69 cases)using a random number table method.The neurological deficits,clinical efficacy,daily living abilities,serum inflammatory factor levels,and adverse reactions were compared between the two groups before treatment and after three treatment courses.Results After three treatment courses,the National Institutes of Health Stroke Scale scores of patients in the observation group and the control group((5.67±1.89)points and(7.88±2.12)points,respectively)were significantly lower than those before treatment((12.34±2.56)points and(12.12±2.45)points,respectively),with statistically significant differences(t=17.412,10.871,both P<0.05),and the level in the observation group was signifi-cantly lower than that in the control group(t=6.464,P<0.05).The observation group demonstrated a significantly higher total effective rate compared to the control group(91.30%(63/69)vs 78.26%(54/69)),with a statistically significant difference(χ2=4.549,P<0.05).After treatment,the scores of the activities of daily living scale in the observation group and the control group((74.57±9.18)points and(67.88±8.43)points,respectively)were significantly higher than those before treatment((45.76±8.90)points and(46.11±8.77)points,respectively),with statistically significant differences(t=18.717,14.866,both P<0.05),and the lev-el in the observation group was significantly higher than that in the control group(t=4.459,P<0.05).After treatment,the levels of interleukin-6 and tumor necrosis factor-α in the observation group and the control group((18.65±3.69)pg/mL,(25.04±4.22)pg/mL,(22.42±3.81)pg/mL,(29.96±4.89)pg/mL,respectively)were significantly lower than those before treatment((35.58±5.27)pg/mL,(43.08±6.65)pg/mL,(36.10±5.86)pg/mL,(42.65±6.78)pg/mL,respectively),with statistically significant differences(t=21.859,19.026,16.257,12.610,all P<0.05),and the levels in the observation group were significantly lower than those in the control group(t=5.904,6.327,both P<0.05).The incidence of adverse reactions in the two groups(14.49%(10/69)vs 11.59%(8/69))showed no statistically significant difference(χ2=0.256,P=0.613).Conclusion The combination of Xueshuantong and edara-vone dexborneol can improve neurological function,enhance daily living abilities,reduce the levels of inflammatory factors in patients with ALACI,and demonstrate good safety.Its clinical efficacy is superior to that of edaravone dexborneol monotherapy.
Keywords：Xueshuantongedaravone dexborneollarge-artery atherosclerosiscerebral infarctionneurological func-tioninflammatory factorclinical efficacy
Publication Date：2025-11-25
Online Publishing Date：2025-12-04(First online date of this platform, not the publication date of the document)
Pages：5( 1309-1313 )